Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from NeOnc Technologies Holdings, Inc. ( (NTHI) ) is now available.
NeOnc Technologies Holdings, Inc. announced significant corporate and clinical developments for Q3 2025. The company reported progress in its NEO100 and NEO212 clinical trials, with NEO100 showing promising Phase 2a results for recurrent brain cancer. Additionally, NeOnc secured a $50 million partnership with Quazar Investment and received $2.5 million in NIH funding, enhancing its financial and strategic positioning. The appointment of key leadership figures and inclusion in the Russell Microcap Index further bolster its market visibility and institutional investor exposure. These developments indicate a strengthened foundation for NeOnc’s long-term growth and innovation in CNS oncology.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics to overcome the blood-brain barrier. The company’s NEO drug development platform includes novel drug candidates like NEO100 and NEO212, which are in Phase II clinical trials and have demonstrated positive effects in treating malignant gliomas.
Average Trading Volume: 79,228
Technical Sentiment Signal: Strong Buy
Current Market Cap: $226.7M
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.